Summary/Abstract The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) was formed as a consequence of several NIH-sponsored workshops focused on defining important research goals for improving care of patients with pancreatic diseases. The goals of the CPDPC have been to investigate the clinically important inter-relationships between pancreatitis, diabetes, and pancreatic cancer, focused on better understanding mechanisms, pathophysiology, and natural history, on improving early diagnosis, discovering specific biomarkers, and ultimately serving as a platform for exploratory and subsequent larger-scale clinical trials. The CPDPC undertook these efforts through the establishment of several prospective patient cohorts, coordinated and planned through the formation of several working groups. These working groups (WGs) include the CP Adult WG, CP Pediatric WG, DM PDAC WG, and the Type3C DM WG. The PROCEED cohort, organized by the CP Adult WG, will ultimately include 1600 adult subjects, and is focused on patients with acute, acute relapsing, and chronic pancreatitis. The INSPIRRE 2 cohort, organized by the CP Pediatric WG, will be comprised of 860 children with acute relapsing and chronic pancreatitis. The DETECT cohort, organized by the Type3C DM WG, is recruiting subjects with typical Type 2 diabetes mellitus as well as patients with diabetes due to pancreatic cancer or chronic pancreatitis, to determine mechanistic differences between these types of diabetes and leverage that information for biomarker and therapeutic benefit. Each cohort will represent a large sample of deeply phenotyped and characterized subjects, with comprehensive annotated biospecimen (biologic samples, radiographic) collection, who are being followed over time. These cohorts, when fully recruited and followed-up, provide a unique and powerful resource to address many unanswered clinical questions and to address the goals of the CPDPC charter. The CPDPC is organized to allow numerous ancillary studies to proceed in parallel to the main cohort recruitment, and these ancillary studies now number more than 50. These ancillary studies have helped inform the work of the CPDPC, and established a set of methods and protocols to guide the consortium, as well as provide defined methods and definitions for future clinical research in these diseases. The structure of the CPDPC provides an unparalleled opportunity for internal and external collaboration to foster clinical studies and develop more effective prediction, prevention, and treatment of complex pancreatic diseases.